Empowering Better Communication among Community Healthcare Stakeholders

The challenges healthcare executives and administrators face are constantly changing. Host Kevin Stevenson talks with the heroes behind the heroes that are enabling hospitals, urgent care centers and telemedicine operators to spend their time tending to patients, while they handle the logistics.

 

On this episode of I Don’t Care, host Kevin Stevenson talks with Ted Quinn, the CEO and Co-founder of Activate Care, a digital health company helping everybody engaged in the healthcare system – clinicians, patients, families, and communities – act together to make health happen, wherever they are.

The duo dug into CIEs* or a Community Information Exchange platform. During the pandemic around the country, many healthcare organizations struggled to communicate between parties. Many of these issues could be solved if important information about patients and care could be shared between stakeholders.

“A community information exchange is a platform that enables all those stakeholders in a community, like a town or a county, to come together and share its space” – Ted Quinn

If these stakeholders can share this information, they can come together to drive the outcomes they want to see.

The pandemic highlighted some of the issues that these community organizations lacked. Some of these things include having different terminologies, priorities, incentive programs, and how they communicate. The goal moving forward is to have these organizations communicate with each other so care is improved for patients.

*Community Information Exchange’ and/or ‘CIE’ are registered trademarks of Community Information Exchange, Inc., and no claim of ownership is made thereto by any use herein.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More